SCHEMBL6733229

SCHEMBL6733229

O=C(O)C(NS(=O)(=O)Cc1ccc2ccccc2c1)c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC1A3 P43003 3/20 0.44
SLC1A2 P43004 3/20 0.44
SLC1A1 P43005 3/20 0.44
ADAMTS4 O75173 1/20 0.43
MMP13 P45452 1/20 0.43
CA2 P00918 1/20 0.42
KMT2A Q03164 1/20 0.42
ATM Q13315 1/20 0.42
CYP1A2 P05177 1/20 0.41
FNTA P49354 1/20 0.41
FNTB P49356 1/20 0.41
KAT6A Q92794 2/20 0.40
PPARG P37231 1/20 0.40
PPARD Q03181 1/20 0.40
PPARA Q07869 1/20 0.40
MMP9 P14780 1/20 0.40
MMP8 P22894 1/20 0.40
MME P08473 1/20 0.39
ACE P12821 1/20 0.39
CPA1 P15085 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6733224 1.00 SLC1A3 (0.44) SLC1A3SLC1A2SLC1A1ADAMTS4MMP13
SCHEMBL6738796 0.88 MEP1B (0.45) MMP13MMP9MMP8
SCHEMBL6738793 0.88 MEP1B (0.45) MMP13MMP9MMP8
SCHEMBL12044424 0.84 SLC1A3 (0.59) SLC1A3SLC1A2SLC1A1MMP13CA2
SCHEMBL6741909 0.83 CTNNB1 (0.41) SLC1A3SLC1A2SLC1A1CA2KMT2A
SCHEMBL7467263 0.81 SLC1A3 (0.38) SLC1A3SLC1A2SLC1A1MMP13CA2
SCHEMBL6738452 0.78 MME (0.48) ADAMTS4MMP13CA2KMT2AMMP9
SCHEMBL6738450 0.78 MME (0.48) ADAMTS4MMP13CA2KMT2AMMP9
SCHEMBL6841965 0.78 MMP7 (0.48) SLC1A3SLC1A2SLC1A1ADAMTS4MMP13
SCHEMBL6841969 0.78 MMP7 (0.48) SLC1A3SLC1A2SLC1A1ADAMTS4MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040225006-A1 (Hetero) bicyclymethanesulfonylamino-substituted hydroxamic acid derivates SMITHKLINE BEECHAM P.L.C. 2004-11-11 US disclosed
US-20030199571-A1 (Hetero) Bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives SMITHKLINE BEECHAM P.L.C. (GB) 2003-10-23 US disclosed
EP-1244616-A1 (HETERO)BICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES SmithKline Beecham plc (GB) 2002-10-02 EP disclosed
WO-2001047874-A1 (HETERO)BICYCLYMETHANESULFONYLAMINO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES SMITHKLINE BEECHAM P.L.C. (GB) 2001-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199571-A1 (Hetero) Bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives CD40, CD22, CD2 SLC1A3 403/4885SLC1A2 1833/4885SLC1A1 644/4885
US-20040225006-A1 (Hetero) bicyclymethanesulfonylamino-substituted hydroxamic acid derivates CD40, TNFRSF1A, CD2 SLC1A3 367/4885SLC1A2 1919/4885SLC1A1 562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.